A kit formulation for preparation of [111In]In-DTPA-folate, a folate- receptor-targeted radiopharmaceutical

Nuclear Medicine and Biology

Volumn 25, Issue 6, 1998, Pages 585-587

  Mathias, Carla J ^a   Green, Mark A ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; INDIUM 111; PENTETATE FOLIC ACID IN 111; PENTETATE INDIUM IN 111; RADIOPHARMACEUTICAL AGENT; RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG FORMULATION; DRUG STRUCTURE; DRUG SYNTHESIS;

CARRIER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FOLIC ACID; INDIUM RADIOISOTOPES; ISOTOPE LABELING; PENTETIC ACID; RADIOPHARMACEUTICALS; RECEPTORS, CELL SURFACE;

EID: 0031871186     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00030-4     Document Type: Article

References (17)

1. Antony A.C. The biological chemistry of folate receptors. Blood. 79:1992;2807-2820.
2. Antony A.C., Kane M.A., Portillo R.M., Elwood P.C., Kolhouse J.F. Study of the role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate. J. Biol. Chem. 260:1985;14911-14917.
3. Campbell I.G., Jones T.A., Foulkes W.D., Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 51:1991;5329-5338.
4. Coney L.R., Tomassetti A., Carayannopoulos L., Frasca V., Kamen B.A., Colnaghi M.I., et al. Cloning of a tumor-associated antigen MOv18 and MOv19 antibodies recognize a folate-binding protein . Cancer Res. 51:1991;6125-6132.
5. DuBeshter B., Lin J., Angel C., Poulter C.A. Gynecologic tumors. Rubin P. Clinical Oncology. 7th edn. 1993;363-418 W. B. Saunders, Philadelphia.
6. Garin-Chesa P., Campbell I., Saigo P., Lewis J., Old L., Rettig W. Trophoblast and ovarian cancer antigen LK26 Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein . Am. J. Pathol. 142:1993;557-567.
7. Kamen B.A., Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc. Natl. Acad. Sci. USA. 83:1986;5983-5987.
8. Li P.Y., Del Vecchio S., Fonti R., Carriero M.V., Potena M.I., Botti G., et al. Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography. J. Nucl. Med. 37:1996;665-672.
9. Mathias C. J., Wang S., Lee R. J., Waters D. J., Low P. S. and Green M. A. (1996a) Tumor selective radiopharmaceutical targeting via receptor-mediated endocytosis: Evaluation of a gallium-67 labeled deferoxamine-folate conjugate. J. Nucl. Med. 37, 1003-1008.
10. Mathias C. J., Wang S., Waters D. J., Low P. S. and Green M. A. (1996b). Ga-67 and In-111-labeled folate-chelate conjugates for targeting tumor-associated folate binding protein. J. Nucl. Med. 37, 347P-348P (Abstract).
11. Mathias C.J., Wang S., Waters D.J., Turek J.J., Low P.S., Green M.A. Indium-111-DTPA-Folate as a radiopharmaceutical for targeting tumor-associated folate binding protein (FBP). J. Nucl. Med. 38:1997;133P-134P. (Abstract).
12. 111In-DTPA-Folate as a potential folate-receptor-targeted radiopharmaceutical. J. Nucl. Med. (in press).
13. McHugh M., Cheng Y.C. Demonstration of a high affinity folate binder in human cell membranes and its characterization in cultured human KB cells. J. Biol. Chem. 254:1979;11312-11318.
14. Miotti S., Canevari S., Menard S., Mezzanzanica D., Porro G., Pupa S.M., et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer. 39:1987;297-303.
15. Toffoli G., Cernigoi C., Russo A., Gallo M.A., Bagnoli M., Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer. 74:1977;193-198.
16. 111In]DTPA-Folate for use as a tumor-targeted radiopharmaceutical. Bioconj. Chem. 8:1997;673-679.
17. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski V.R. Jr, et al. Distribution of the folate receptor (GP38) in normal and malignant cell lines and tissues. Cancer Res. 52:1992;3396-3401.